Skip to content
Companies

Cue Biopharma

Biologics that modulate disease-specific T cells

Raised to date

$80M

of $80M offered across 2 Form D filings

Investors
118
Last filed
Jul 22, 2026

About

Cue Biopharma is a clinical-stage biopharmaceutical company in Boston, Massachusetts developing a novel class of injectable biologics that selectively engage and modulate disease-specific T cells directly within the patient's body. Its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform is designed to harness the immune system without the adverse effects of broad systemic immune modulation. The company has refocused its portfolio on allergic and autoimmune disease, led by CUE-221, an anti-IgE antibody with a dual mechanism of action in Phase 2, and CUE-401, a bifunctional IL-2 and TGF-beta program advancing toward Phase 1. Earlier immuno-oncology programs including CUE-101 and CUE-102 came out of the same platform, and the company has partnered with Boehringer Ingelheim on autoimmune disease.

Immuno-STAT biologics are engineered to modulate only disease-specific T cells in vivo, aiming for functional cures in allergy and autoimmunity without the broad immunosuppression that limits conventional therapies.

Funding

$50M, first sold Jul 2026$50M soldMay 2026Aug
Now
  • EquityFiled Jul 22, 2026Form D
    $50M/ $50M
  • Security to be acquiredFiled May 14, 2026Form D
    $30M/ $30M

Product

Immuno-STAT platform

Biologics drug discovery platform

A proprietary biologics platform — Selective Targeting and Alteration of T cells — that engineers injectable fusion biologics to selectively engage and modulate disease-specific T cells in vivo, and the source of the company's clinical and preclinical pipeline.

  • Injectable biologics rather than cell therapy, dosed in vivo
  • Selective engagement of disease-specific T cells
  • Avoids broad systemic immune modulation

Built for

Patients with allergic and autoimmune diseases who have persistent symptoms and significant unmet need, reached through prescribing physicians and pharmaceutical development partners

People on file